HypErtensive Augmentation During acute ischaemic STroke Assisting Reperfusion Therapies

Phase 1

• Conditions: Acute Ischaemic Stroke; Stroke - Ischaemic

• Registration Number: ACTRN12622001055796
• Lead Sponsor: Royal Adelaide Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-07-29
• Last Update Posted: 15 August 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

1) Acute anterior circulation ischaemic stroke with measurable neurologic deficit
2) Demonstration of penumbra of CT perfusion imaging (Delay time (DT) lesion >3 seconds volume > 30 mL, as measured by MiSTAR software)
3) Initial systolic blood pressure on ED presentation below 160mmHg

Exclusion Criteria

1) Known renal failure (eGFR < 30mL)
2) Iodine contrast hypersensitivity
3) Any contraindication to Metaraminol administration ((hypersensitivity to Metaraminol including sulfite allergy, nonselective Monoamine Oxidase Inhibitor (MAO-I) therapy (phenelzine, tranylcypromine) in the past 14 days))
4) <50 years old
5) Previous intracerebral or subarachnoid haemorrhage
6) Presence of an intracranial aneurysm or arteriovenous malformation
7) Presence of an aortic dissection
8) Presence of an acute or recent (<30 days) myocardial infarction
9) Recent (<1 month) left ventricular failure
10) Any other condition which, in the opinion of the Investigator, increases the risk of blood pressure augmentation

Study & Design

• Study Type: Interventional
• Study Design: Not specified